

1 Evaluation of tooth sensitivity after scaling and root planing treated with photobiomodulation: a
2 randomized controlled split-mouth double-blind clinical protocol

3

4 Short title: Tooth sensitivity after scaling and root planing treated with photobiomodulation

5

6 María Victoria García Olazabal^{1,2,#b,#a}, ¶ garciaolazabal@gmail.com

7 Luis Eduardo Pascuali Moya^{1,2,#a,#b}, ¶ dr.luisepm@gmail.com

8 Rolf Wilhem Consolandich Cirisola^{1,2,#a,#b}, ¶ drconsolandich@gmail.com

9 Ana Paula Taboada Sobral^{3,#c}, & anapaula@taboada.com.br

10 Laura Hermida Bruno^{1,2,#b,#a}, ¶ laurahermidabruno@gmail.com

11 Federico Todeschini Safi^{1,2,#b,#a}, ¶ federico.todeschini@ucu.edu.uy

12 Priscila Larcher Longo^{4,#d,#a}, ¶ pllongo@gmail.com

13 Maria Cristina Chavantes^{1#a,&} lunglasertherapy@yahoo.com.br

14 Ricardo Scarparo Navarro^{5,#e}, ¶ ricardosnavarro@gmail.com

15 Cinthya Cosme Gutierrez Duran^{1#a,&} cduran@uni9.pro.br

16 Kristianne Porta Santos Fernandes^{1#a,&} kristianneporta@gmail.com

17 Raquel Agnelli Mesquita Ferrari^{1#a,&} raquel.mesquita@gmail.com

18 Sandra Kalil Bussadori^{1#a,&} sandra.skb@gmail.com

19 Lara Jansiski Motta^{1#a,&} larajmotta@uni9.pro.br

20 Anna Carolina Ratto Tempestini Horliana^{1#a¶*} annacrth@gmail.com

21

22 ¹Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de
23 Julho (UNINOVE), São Paulo, Brazil.

24 ²Universidad Católica del Uruguay (UCU), Montevideo, Uruguay.

25 ³Postgraduation Program in Health and Environment, Universidade Metropolitana de Santos,
26 Santos, Brazil

27 ⁴Postgraduate Program in Aging Science, Universidade São Judas Tadeu (USJT), São Paulo,
28 Brazil

29 ⁵ Universidade Brasil, São Paulo, Brazil

30

31 ^{#a} Current adress: Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.

32 ^{#b} Current adress: Universidad Católica del Uruguay (UCU), Montevideo, Uruguay

33 ^{#c} Current adress: School of Dentistry, Universidade Metropolitana de Santos, Santos, Brazil

34 **NOTE** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 #e Current adress: Universidade Brasil, São Paulo, Brazil

2

3 ¶ These authors contributed equally to this work.

4 & These authors also contributed equally to this work.

5

6 **Corresponding Author:**

7 E-mail: annacrth@gmail.com (ACRTH)

8 **Orcid iD:** 0000-0003-3476-9064

9 • **Data availability Statement-** all data will be available for the readers.

10 • **Funding Statement** - The project received a government grant (National Council for
11 Scientific and Technological Development – CNPq- process: 3146682020-9). In this
12 study the funder only will provide support and resources but will not hold ultimate
13 authority over study design, data collection, analysis, report writing, or publication
14 decisions, ensuring scientific integrity and independence

15 • **Conflict of interest disclosure** All authors disclose any financial and personal
16 relationships with other people or organizations that could inappropriately influence
17 (bias) this study.

18 • **Ethics approval Statement** - The project received approval from the Research Ethics
19 Committee of Universidad Católica del Uruguay (UCU), (process: 30052022)

20 • **Patient consent Statement** – All the participants included signed an Informed consent.
21 The CI document was in writing.

22 • **Clinical trial registration:** NCT05946265 (initial release: July 2023)

23 • **Dissemination policy** We will disseminate the trial findings to participants, healthcare
24 professionals, and the general public. Comprehensive data, along with results, will be
25 shared through both complete datasets and results databases while adhering to any
26 publication restrictions. Moreover, we are committed to facilitating potential public
27 access to the full protocol, participant-level dataset, and statistical code. These measures
28 emphasize our unwavering dedication to maintaining transparency

29 • **Author contributions:** Conceptualization; Horliana ACRT, Fernandes KPS, Motta LJ,
30 Bussadori SK; Methodology: Horliana ACRT, Mesquita-Ferrari AR, Sobral APT; Project
31 administration; Bussadori SK; Cirisola RWC; Resources Olazabal MVG, Safi FT;
32 Supervision; Fernandes KPS, Bussadori SK, Mesquita-Ferrari AR; Navarro RS;
33 Validation; Motta LJ, Mesquita-Ferrari AR; Bruno LH, Chavantes MC, Duran CCG;
34 Roles/Writing Moya LEP, Cirisola RWC Olazabal MVG; Longo PL

35

1 Abstract

2

3 It is well known that hypersensitivity affects patients recently treated with scaling and root
4 planing. Some studies have demonstrated that photobiomodulation (PBM) can alleviate dentinal
5 hypersensitivity by modulating pain. However, to date, there is no established protocol for its
6 application after scaling and root planning. To evaluate tooth hypersensitivity after
7 photobiomodulation in sensitive scaling and root planning treated teeth. Study design:
8 Randomized, controlled, double-blind split-mouth clinical trial. Methods: Forty-four patients
9 with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly
10 included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W,
11 area 0,5cm², 200w/cm², 30 seconds, 3 J, 6J/cm²) and Control Group: Scaling and root planning
12 +FBM simulation. After 7 days of scaling and root planning, all patients will be evaluated for
13 hypersensitivity. The cutoff of VAS will be 3. These patients will be included in the study. The
14 primary outcome of the study will be the assessment of dentin hypersensitivity after 7 days of
15 RAR measured with the visual analog scale (VAS). Also, it will be assessed the impact of oral
16 health on the participant's quality of life, with the OHIP-14 questionnaire. The use of analgesics
17 (paracetamol) will be prescribed as needed and the amount of medication will be calculated.
18 These outcomes will be evaluated after 7 days and 1 month of application. If the data are normal,
19 they will be submitted to the ANOVA test – one way. Data will be presented as means ± SD and
20 the p-value will be set to < 0.05.

21

22 **Keywords:** photobiomodulation, periodontal treatment, low-level light therapy, Dentin
23 Sensitivity

24

25 Introduction

26 Periodontitis is a disease associated with subgingival biofilm adhered to tooth surfaces,
27 which generates a chronic inflammatory response that is unable to interrupt the infectious process
28 and causes progressive destruction of the supporting periodontium (Papapanou et al. 2018).

29 Periodontal therapy for the management of chronic periodontitis requires non-surgical or
30 surgical intervention to establish healthy periodontal conditions (Alpiste 2006). However, active
31 periodontal therapy causes undesirable sequelae, such as gingival recession or exposure of
32 dentinal tubules, which causes dentin hypersensitivity (Romero 2009). In a previous study (Sobral
33 et al., 1992), of 32 patients with dentin hypersensitivity, 41% had received periodontal treatment

1 and of these, 29% had undergone periodontal surgery. Another study (Hastings 2002) reported
2 that dentin hypersensitivity after periodontal surgery can last for months or indefinitely. Pain
3 arising from the exposed root surface is the most common complaint of patients after undergoing
4 periodontal therapy, however, there is little clinical research dedicated to its treatment (Raut 2018,
5 Corona 2003, Hastings 2002, Sobral 1999, Fischer 1992).

6 To handle hypersensitivity, treatment with lasers has been proposed (Sgolastra 2013). Laser
7 mechanism action at hypersensitivity is not clearly understood, although several theories have
8 been proposed. High-power lasers (e.g. Er: YAG, Nd: YAG and Er, Cr: YSSG) can reduce or
9 obliterate dentinal tubules by the melting effect on the superficial heat production in cementum
10 (Sgolastra et al., 2011). As for low-intensity lasers, photobiomodulation (FBM) in the dental pulp
11 can cause increased cellular metabolic activity of odontoblasts, intensifying the production of
12 tertiary dentin, causing obliteration of dentinal tubules (Sgolastra 2013, Ladalardo 2004).

13 The advantage of using low-power lasers is that they are safer, do not emit heat, and are
14 more accessible for clinical practitioners (Ladalardo 2004). For these reasons, the objective of
15 this study will be to evaluate tooth sensitivity after photobiomodulation in sensitive scaling and
16 root-planning-treated teeth.

17

18 **Material e métodos**

19

20 This is a randomized, controlled, double-blind split-mouth clinical trial. It was designed according
21 to the SPIRIT Statement (Figure 1). It was submitted and accepted by the Research Ethics
22 Committee (CEP) of the Catholic University of Uruguay (#30052022). The treatments will be
23 carried out at the Periodontology Clinic II, of the Catholic University of Uruguay in the city of
24 Montevideo, Uruguay, from September 2023 to June 2024. The project has been registered on the
25 ClinicalTrials.gov website (NTC05924204) on 06th June 2023. It is not expected to change the
26 protocol, however any important protocol modifications will be communicated to the Ethical
27 Committee and Clinical Trial Registry. This study does not include minors. All the participants
28 provided informed consent (written and verbal). This document was approved by our Ethics
29 Committee. This study does not report a retrospective study of medical records or archived
30 samples. Any future changes to the study will be promptly reported to the CEP and will be
31 disclosed in subsequent publications. A signed copy of the informed consent form will be
32 provided to each participant.

33 *Sample description* - Participants in need of periodontal treatment (scaling and root planning)
34 who seek the service of the Clinic of Periodontics II at the Catholic University of Uruguay with
35 a diagnosis of Periodontitis, stage I, II III, or IV will be recruited by researcher 2. All patients

1 included will receive initial periodontal therapy (educational and preventive interventions and
2 removal of local retentive factors) and the second stage (Scraping and root planning). After a
3 week, they will be probed in the cervical region of all teeth and if there is pain greater than 3 on
4 the VAS, they will be included in the study.

5 *Inclusion and exclusion criteria* - Patients over 18 years of age, both genders, without
6 comorbidities, will be included. Patients who are taking drugs that affect gingival metabolism
7 (cyclosporine, phenytoin, nifedipine), inflammatory medicine (: corticosteroids or non-steroidal
8 anti-inflammatory drugs), or analgesics, pregnant or lactating women, those with photosensitivity
9 history and allergic to paracetamol will be excluded.

10 *Sample size calculation* - The sample size will be 22 patients in each group. This value was
11 calculated to provide a power of 90% ($\alpha = 0.05$). To determine the necessary n for each group, a
12 sample calculation was performed based on a similar previous study (Ko 2014) which evaluated
13 the outcome pain decrease, measured with the VAS scale. In this study (Ko, 2014) we considered
14 an average of 3 for the experimental group and 5 for the control group. The standard deviation
15 considered for the calculation was ± 2 , the highest among the groups. A total of 22 patients will
16 be required for each group which totalizes 44 hemiarcs (Split mouth).

17 *Examiner training* – The main researcher will be trained to use the visual analogue scale and
18 collect data from the OHIP-14, aiming to maximize the reproducibility of the evaluations.

19 *Randomization:* We will use a random sequence generator website
20 (<https://www.sealedenvelope.com/>) and select the randomization option of 24 blocks with 2
21 hemiarcs. The randomization will be implemented on the right side, and the opposite treatment
22 will be applied on the left side. Opaque envelopes will be numbered sequentially and each will
23 contain information about the corresponding group based on the generated order. These envelopes
24 will remain sealed in a secure location until the moment of interventions with FBM or simulation.
25 The randomization process will be managed by an individual who is not directly involved in the
26 study. We have included an additional 6 hemiarcs in the sample (44 hemiarcs in total) to
27 account for potential losses.

28 *Blinding* - Immediately after periodontal treatment, the researcher responsible for applying the
29 FBM will remove and open one envelope and perform the indicated procedure (FBM or
30 simulation). Only this researcher will know the intervention applied to each patient (Researcher
31 1). All the other investigators will be blinded to the intervention (researcher 2 - recruitment and
32 researcher 3 - data collection/outcomes) Allocation will not be revealed to participants during the
33 study. I will ensure the confidentiality of personal data for potential and enrolled participants
34 through secure collection, sharing, and maintenance protocols, utilizing a computer with no
35 internet access, password protection, and data encryption stored on a USB drive

1 *Pre-treatment assessments* - Anamnesis, and periodontal examination will be performed. All
 2 participants will receive guidance on oral hygiene (HBO), brushing with the Bass technique,
 3 specifications regarding the toothbrush (soft bristles and small head), dental floss (traditional
 4 Colgate®), and scaling and root planning treatment. After one week, periodontal probing will be
 5 performed before laser (or simulation application) on treated teeth to assess sensitivity (>3- VAS
 6 scale) after root scaling.

7 All activity performed will be recorded, as well as the amount of medication ingested for pain
 8 sensitivity, besides OHIP-14 questionnaires.

9 *Composition of the groups* - The 44 hemiarc (22 patients) will be allocated into the groups as
 10 follows:

11 *Experimental Group* – RAR + FBM (n=22): The researcher responsible for FBM will remove the
 12 randomization envelope and apply Laser Therapy XP (Figure 2) at the points indicated in Figure
 13 3. All dosimetric parameters, details of sessions, and the number of FBM applications are
 14 described in Table 1.

15 The equipment description, dosimetric parameters, and number of FBM applications are detailed in Table 1.

Dosimetric parameters	Values/treatment
Wavelength [nm]	660 nm
Operating mode	Continuous
Radiant power [mW]	100 mW / 0.1 W
Irradiance [mW/cm ²]	35.385 mW/cm ² - 35 W/cm ²
Beam area [cm ²]	0.002826 cm ²
Exposure time [s]	30 seconds per point
Radiant exposure [J/cm ²]	1.061 J/cm ²
Radiant energy [J]	3 J
Number of irradiated points	6 points per tooth divided into: Vestibular (1 apical, 1 middle, and 1 cervical) and palatal
Application technique	In contact, at a 90-degree angle to the surface
Number of sessions and frequency	One time only

16

17 Table 1: Dosimetric Parameters

18

1 *Control Group* – RAR + FBM simulation (n=22): Simulation of the use of FBM will be carried
2 out identically to the Experimental group. The person responsible for applying the FBM will
3 simulate irradiation by positioning the devices in the same locations described for the FBM group,
4 however, the laser pointer will be turned off and the sound of the device will be recorded to mimic
5 the use of the equipment, so, participants will not identify to which group they are part of. In this
6 trial, we have no criteria for discontinuing or modifying allocated interventions because no harm
7 is expected with this intervention. The study flowchart presents the details of the project (Figure
8 4).

9 *Relevant concomitant care and interventions that are permitted or prohibited during the trial* –
10 patients should not take analgesics for dentin hypersensitivity other than paracetamol. Any other
11 mediation (described in the exclusion criteria) will influence the analgesic count in the evaluated
12 period.

13 *Primary outcome*

14 *Pain* - It will be evaluated through the application of the Visual Analog (VAS) with a 10cm ruler
15 in length of 10 cm, with no mark. One of the extremes is marked “0”, and the other “100” which
16 means respectively “no pain” and “unbearable pain”. This rule will be the same for all
17 participants. Instructions on marking will always be given to the patient by the same operator.
18 Each participant will be instructed to mark with a vertical line the point that best corresponds to
19 the intensity of pain at the time of assessment (Bottega, 2010). Without the presence of the
20 participant, the operator will measure this mark with the same ruler, recording this data on the
21 research clinical record. This analysis will occur on all periods (baseline, 7, and 30 days).

22 *Secondary outcomes*

23 *Rescue medication* - Another parameter analyzed will be the quantity of analgesics ingested, as
24 proposed by Bauer, 2013. At the beginning of the research, a pack of paracetamol® will be given
25 to each participant (Józwiak-Bebenista, 2014) and the use will be prescribed in case of pain. At
26 the end of the experiment, the number of pills will be evaluated as another pain measurement
27 parameter (drug tablet return). To monitor the participant's adherence they will be asked to take
28 the pack of analgesics to each consultation checking how they will be used. The participant will
29 be oriented to use only paracetamol, not other medicines.

30 *Analysis of the impact of oral health on the individual's quality of life through the application of*
31 *the OHIP-14 questionnaire (Oral health impact profile questionnaire - Ohip-14)*- The Ohip-14
32 will be used to assess the impact of oral health on the participant's quality of life (Slade, 1997).
33 To quantify the Likert scale, we will use the additive method – Points will be summed (0-56),
34 with 56 having the greatest impact on quality of life. This is validated and translated into a
35 Portuguese questionnaire (Riva, 2022).

1 Any changes in the protocol will be communicated to the Ethics Committee.

2 *Analysis of results* - Initial descriptive analyses will consider all the variables measured in the
3 study, both quantitative (mean and standard deviation) and qualitative (frequencies and
4 percentages). Subsequently, normality analyses will be performed to determine the appropriate
5 statistical tests for each data set and the appropriate statistical tests will be applied for each
6 specific analysis. In all tests, the significance level of 5% of probability or the corresponding p-
7 value will be adopted. All analyses will be performed using the statistical program SPSS for
8 Windows, version 9.1. The data of all patients randomized for the research will be included in the
9 statistical analysis, described, and discussed, as well as the possible adverse effects. Adverse
10 events will be questioned for all participants during the experiment. However interim analyses
11 will not plan because adverse events are not expected in this trial.

12

13 **References**

14

15 Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R,
16 Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF,
17 Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A,
18 Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report
19 of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-
20 Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi:
21 10.1002/JPER.17-0721. PMID: 29926951.

22

23 Alpiste Illueca FM, Buitrago Vera P, de Grado Cabanilles P, Fuenmayor Fernandez V, Gil Loscos
24 FJ. Periodontal regeneration in clinical practice. Med Oral Patol Oral Cir Bucal. 2006 Jul
25 1;11(4):E382-92. English, Spanish. PMID: 16816809.

26

27 Amaro R, Ilusión M; Escalona L, Acevedo, AM. Teorías y factores etiológicos involucrados en la
28 hipersensibilidad dentinaria. Acta odontol. venez [online]. 2009, vol.47, n.1, pp. 260-269. ISSN
29 0001-6365.

30

31 Sobral M, Garone Netto N, Luz M, Santos A. Aspectos clínicos da etiologia da
32 hipersensibilidade dentinaria cervical. Rev Odontol Univ Sao Paulo 1999; 13(2):189-195.

33

34 Hastings C. Hipersensibilidad dentinaria, higiene dental y consideraciones periodontales. Int Dent
35 J 2002; 52: 385-393.

36

37 Raut CP, Sethi KS, Kohale BR, Mamajiwala A, Warang A. Indocyanine green-mediated
38 photothermal therapy in treatment of chronic periodontitis: A clinico-microbiological study. J
39 Indian Soc Periodontol. 2018 May-Jun;22(3):221-227. doi: 10.4103/jisp.jisp_128_18. PMID:
40 29962701;

41

- 1 Fischer C, Fischer RG, Wennberg A. Prevalence and distribution of cervical dentine
2 hypersensitivity in a population in Rio de Janeiro, Brazil. *J Dent*. 1992 Oct;20(5):272-6. doi:
3 10.1016/0300-5712(92)90043-c. PMID: 1452864.
- 4
- 5 Corona SA, Nascimento TN, Catirse AB, Lizarelli RF, Dinelli W, Palma-Dibb RG. Clinical
6 evaluation of low-level laser therapy and fluoride varnish for treating cervical dentinal
7 hypersensitivity. *J Oral Rehabil*. 2003 Dec;30(12):1183-9. doi: 10.1111/j.1365-
8 2842.2003.01185.x. PMID: 14641661.
- 9
- 10 Ladalardo TC, Pinheiro A, Campos RA, Brugnera Júnior A, Zanin F, Albernaz PL, Weckx LL.
11 Laser therapy in the treatment of dentine hypersensitivity. *Braz Dent J*. 2004;15(2):144-50. doi:
12 10.1590/s0103-64402004000200011. Epub 2005 Mar 11. PMID: 15776198.
- 13
- 14 Sgolastra F, Petrucci A, Severino M, Gatto R, Monaco A. Lasers for the treatment of dentin
15 hypersensitivity: a meta-analysis. *J Dent Res*. 2013 Jun;92(6):492-9. doi:
16 10.1177/0022034513487212. Epub 2013 Apr 22. PMID: 23609160.
- 17
- 18 Sgolastra F, Petrucci A, Gatto R, Monaco A. Effectiveness of laser in dentinal hypersensitivity
19 treatment: a systematic review. *J Endod*. 2011 Mar;37(3):297-303. doi:
20 10.1016/j.joen.2010.11.034. PMID: 21329811.
- 21
- 22 Ko Y, Park J, Kim C, Park J, Baek SH, Kook YA. Treatment of dentin hypersensitivity with a
23 low-level laser-emitting toothbrush: double-blind randomized clinical trial of efficacy and
24 safety. *J Oral Rehabil*. 2014 Jul;41(7):523-31. doi: 10.1111/joor.12170. Epub 2014 Apr 10.
25 PMID: 24717149.
- 26
- 27 Sealed Envelope Ltd. 2021. Create a blocked randomization list. [Online] Available from:
28 <https://www.sealedenvelope.com/simple-randomiser/v1/lists> [Accessed 2 Sep 2022].
- 29
- 30 Bauer HC, Duarte FL, Horliana AC, Tortamano IP, Perez FE, Simone JL, Jorge WA.
31 Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone
32 in third molar surgery: a randomized double-blind controlled clinical trial. *Oral Maxillofac*
33 *Surg*. 2013 Sep;17(3):165-71. doi: 10.1007/s10006-012-0360-7. Epub 2012 Sep 5. PMID:
34 22949122.
- 35
- 36 Józwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety
37 concern. *Acta Pol Pharm*. 2014 Jan-Feb;71(1):11-23. PMID: 24779190.
- 38
- 39 Slade GD. Derivation and validation of a short-form oral health impact profile. *Community*
40 *Dent Oral Epidemiol*. 1997 Aug;25(4):284-90. doi: 10.1111/j.1600-0528.1997.tb00941.x.
41 PMID: 9332805.
- 42
- 43 Riva F, Seoane M, Reichenheim ME, Tsakos G, Celeste RK. Adult oral health-related quality of
44 life instruments: A systematic review. *Community Dent Oral Epidemiol*. 2022 Oct;50(5):333-
45 338. doi: 10.1111/cdoe.12689. Epub 2021 Aug 18. PMID: 34409626.



medRxiv preprint doi: <https://doi.org/10.1101/2023.09.28.23296306>; this version posted October 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a [CC-BY 4.0 International license](#).


Figure 3. Therapy EC (DMC) equipment for FBM application



Figure 2 - Laser application on the buccal surface (source: adapted from google.com/images)

medRxiv preprint doi: <https://doi.org/10.1101/2023.09.28.23296306>; this version posted October 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4. Study flowchart



medRxiv preprint doi: <https://doi.org/10.1101/2023.09.28.23296306>; this version posted October 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

TIME	STUDY PERIOD				
	RECORD	RANDOMIZA TION	POS OPERATIVE		CLOSURE
	-T ₁	0	T ₀	T ₁ (7 d)	T ₃ (30 d)
RECORD:					
Inclusion/exclusion criteria	X				
Informed consent	X				
Research calibration	X				
Assignment		X			
INTERVENTIONS:					
Experimental group			X		
Control group			X		
OUTCOMES:					
VAS (primary)			X	X	X
Analgesics			X	X	X
OHIP-14			X		X

medRxiv preprint doi: <https://doi.org/10.1101/2023.09.28.23296306>; this version posted October 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).